Voyager Therapeutics price target lowered to $12 from $14 at Wells Fargo

Wells Fargo lowered the firm’s price target on Voyager Therapeutics (VYGR) to $12 from $14 and keeps an Overweight rating on the shares. With neuro tox uncovered for SOD1 program in NHPs, the key question is potential readthrough to TRACER platform. NHP data from the tau AAV program showed no neuro tox at doses corresponding to reasonable tau lowering, suggesting the platform is still viable, the firm notes.